Ocugen (OCGN)
(Delayed Data from NSDQ)
$1.29 USD
-0.04 (-3.01%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $1.28 -0.01 (-0.78%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.29 USD
-0.04 (-3.01%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $1.28 -0.01 (-0.78%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
by Zacks Equity Research
OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.
Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
by Zacks Equity Research
Ocugen's (OCGN) shares rise significantly in the year-to-date period on positive progress with its promising pipeline candidates.
Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Ocugen (OCGN) have performed compared to their sector so far this year.
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
by Zacks Equity Research
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.
Ocugen Q2 Preview: Rebound Quarter Inbound?
by Derek Lewis
Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.
Implied Volatility Surging for Ocugen (OCGN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
by Zacks Equity Research
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocugen (OCGN) delivered earnings and revenue surprises of -280% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
by Zacks Equity Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin Study
by Zacks Equity Research
Ocugen (OCGN) is conducting the OCU-002 study to support its BLA for the approval of Covaxin in the United States. The FDA places a clinical hold on this study.
The Zacks Analyst Blog Highlights Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences
by Zacks Equity Research
Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.
Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates
by Zacks Equity Research
Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.
Ocugen (OCGN) Down 23% With FDA Denial of COVID Vaccine EUA
by Zacks Equity Research
The FDA turns down an emergency use authorization request from Ocugen (OCGN) to use its COVID-19 vaccine Covaxin in pediatric population. Stock depreciates.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Ocugen's (OCGN) COVID-19 Booster Effective Against Omicron
by Zacks Equity Research
Ocugen's (OCGN) India-based partner announces robust neutralizing antibody responses against Omicron and Delta variants, following the administration of the booster dose of COVID-19 vaccine, Covaxin.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group
by Zacks Equity Research
Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Company News for Oct 6, 2021
by Zacks Equity Research
Companies in The News Are: PEP, JNJ, OCGN, SPWR.
Do Options Traders Know Something About Ocugen (OCGN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Implied Volatility Surging for Ocugen (OCGN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Ocugen's (OCGN) Q2 Earnings Miss Estimates, Stock Down
by Zacks Equity Research
Ocugen (OCGN) miss earnings estimates in the second quarter of 2021. Stock down.